RTI Biologics investor buys, sell shares for 5.68% stake

By Lisa Kerner

Charlotte, N.C., March 6 - Kopp Investment Advisors, LLC reported a 5.68% ownership interest in RTI Biologics, Inc. following a series of buy and sell transactions between Dec. 29 and Feb. 27, according to a schedule 13D filed with the Securities and Exchange Commission.

The investor beneficially owns 3,071,435 shares of RTI Biologics.

RTI Biologics was formed on Feb. 27 through the merger of Regeneration Technologies, Inc. and Tutogen Medical, Inc.

In addition to its headquarters location in Alachua, Fla., RTI Biologics has an international processing facility in Neunkirchen, Germany, and a distribution office in Boulogne, France.

RTI Biologics prepares human donated tissue and bovine tissue for transplantation. The allograft (human) and xenograft (animal) implants are used in orthopedic, dental, hernia and other specialty surgeries.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.